Clinical Trial Update: A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated the effectiveness and tolerability of BI 655130 in patients with atopic dermatitis, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• BI 655130

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Dermatitis, Atopic | Phase 2 | Status: COMPLETED | Results posted: 2022-12-01